RIMKLA

N-acetylaspartylglutamate synthase A · Q8IXN7 · RIMKLA on Sugi Atlas →

4,958 patent compounds predicted against RIMKLA, 3,623 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1377049	1.00	1/20
SCHEMBL1374248	0.81	1/20
SCHEMBL148582	0.75	1/20
SCHEMBL148583	0.75	1/20
SCHEMBL1292670	0.75	1/20
SCHEMBL4147358	0.75	1/20
SCHEMBL1741931	0.72	1/20
SCHEMBL2450650	0.72	1/20
SCHEMBL2450656	0.72	1/20
SCHEMBL4669761	0.72	1/20
Acetylglutamic Acid (SCHEMBL82128)	0.69	1/20
Aceglumate (SCHEMBL198970)	0.69	1/20
Carglumic Acid (SCHEMBL373546)	0.69	1/20
Acetylglutamic Acid (SCHEMBL716411)	0.69	1/20
Carglumic Acid (SCHEMBL910483)	0.69	1/20
Carglumic Acid (SCHEMBL910527)	0.69	1/20
SCHEMBL1533825	0.69	1/20
SCHEMBL2375284	0.69	1/20
Acetylglutamic Acid (SCHEMBL2512801)	0.69	1/20
SCHEMBL3506183	0.69	1/20

Clinical trials — most relevant to RIMKLA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease	PHASE4	COMPLETED
Minocycline for Bipolar Depression	PHASE4	COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders	PHASE3	RECRUITING
N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia	PHASE2/PHASE3	UNKNOWN
Citalopram to Enhance Cognition in HD	PHASE2	COMPLETED
Lithium and Acetate for Canavan Disease	PHASE2	WITHDRAWN
Folate Rechallenge	PHASE2	COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)	PHASE2	RECRUITING
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia	PHASE2	WITHDRAWN
GTA-Glyceryltriacetate for Canavan Disease	PHASE1	UNKNOWN
Biomarkers of Fast Acting Therapies in Major Depression	PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine	EARLY_PHASE1	COMPLETED
Glutamine Supplementation in People With Immune Dysregulation	EARLY_PHASE1	WITHDRAWN
Treatment Response in Schizophrenia: Bridging Imaging and Postmortem Studies	nan	COMPLETED
Lamotrigine Therapy in Geriatric Bipolar Depression	nan	COMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte	nan	COMPLETED
Neuroimaging of Babies During Natural Sleep to Assess Typical Development and Cerebral Palsy	nan	RECRUITING
Glutamate Probes in Adolescent Depression	nan	COMPLETED
Acute Glycine Pharmacodynamic Study	nan	COMPLETED
Human Epilepsy Genetics--Neuronal Migration Disorders Study	nan	RECRUITING
Biomarker Research in Inherited Movement Disorders	nan	RECRUITING
Protein Synthesis in the Brain of Patients With Fragile X Syndrome	nan	COMPLETED
Dynamic Neuroimaging Biomarkers in Huntington's Disease	nan	COMPLETED
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD	nan	COMPLETED
Pilot Study Evaluating Neuro-Imaging Correlates of Epigenetic Finding in Prediction of Chronic Postsurgical Pain	nan	UNKNOWN
Plant-based Diets and Body Weight and Selected Metabolic Parameters Management in Obese Patients.	nan	COMPLETED
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN)	nan	RECRUITING
L-arginine add-on Therapy in Patients With Schizophrenia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RIMKLA binder may also engage these)

Protein	Name	Similarity
Q0VCE9	—	1.000	Q0VCE9 →
Q6PFX8	—	1.000	Q6PFX8 →
Q9ULI2	—	1.000	Q9ULI2 →
Q66HZ2	—	1.000	Q66HZ2 →
Q80WS1	—	1.000	Q80WS1 →
O23461	—	0.990	O23461 →
Q8BIX9	—	0.990	Q8BIX9 →
B4F6I5	—	0.989	B4F6I5 →
Q7TNL3	—	0.989	Q7TNL3 →
Q17QV9	—	0.989	Q17QV9 →
Q9STV0	—	0.989	Q9STV0 →
B4NBB0	—	0.989	B4NBB0 →
Q5SNQ7	—	0.988	Q5SNQ7 →
Q5BK26	—	0.988	Q5BK26 →
Q6ZV29	—	0.988	Q6ZV29 →
Q9D3R6	—	0.988	Q9D3R6 →
B4IL64	—	0.988	B4IL64 →
Q8GWG2	—	0.988	Q8GWG2 →
AS3MT	Arsenite methyltransferase	0.988	landscape →
KDM5B	Lysine-specific demethylase 5B	0.988	landscape →
A8X181	—	0.988	A8X181 →
E9Q4S1	—	0.988	E9Q4S1 →
A9R2X3	—	0.988	A9R2X3 →
Q8D170	—	0.988	Q8D170 →
Q66DZ1	—	0.988	Q66DZ1 →
A4TPK3	—	0.988	A4TPK3 →
Q8MJ26	—	0.987	Q8MJ26 →
A2RRU1	—	0.987	A2RRU1 →
KDM5D	Lysine-specific demethylase 5D	0.987	landscape →
Q7Z401	—	0.987	Q7Z401 →